Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-existing diagnosis of primary immunodeficiency with features of hypogammaglobulinemia requiring IgG replacement therapy~* No serious bacterial infection within the last 3 months prior to or during Screening~* Currently on IgG replacement therapy (via IV or SC infusion) for ≥3 consecutive months. Subjects receiving IGIV must be receiving a dosage of 300 to 800 mg/kg per infusion~* Documented (at least once within previous 3 months) IgG trough level of ≥500 mg/dL on current IgG replacement therapy regimen~Exclusion Criteria:~* Known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product~* History of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study~* Isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy~* Nephrotic syndrome, and/or a history of acute renal failure and/or severe renal impairment, and/or on dialysis~* History (year prior to Screening or 2 episodes in lifetime ) of or current diagnosis of deep venous thrombosis or thromboembolism (eg, deep vein thrombosis, myocardial infarction, cerebrovascular accident or transient ischemic attack)~* Acquired medical condition known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/μL \[1.0 x 10\^9/L\]), or human immunodeficiency virus infection/acquired immune deficiency syndrome~* Known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection~* Non-controlled arterial hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg in adult subjects)~* Receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids defined as daily dose \>1 mg of prednisone equivalent/kg/day for\>30 days Note: Intermittent courses of corticosteroids of not more than 10 days would not exclude a subject. Inhaled or topical corticosteroids are allowed.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IGIV-C 10% (Type: ACTIVE_COMPARATOR): IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
- IGSC 20% (Type: EXPERIMENTAL): Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)

Based on this trial design, predict the completion outcome and termination type (if applicable).